Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance  COVID-19 status Phase of research How it helps Latest publication
4-Chloro-N-(1-methyl-1H-benzimidazol-5-yl)benzamide
Potential treatment - theoretical effect Experimental Antiviral Nov/23/2020
4-Chloro-N-[1-(2-quinolin-3-ylethynyl)cyclohexyl]-1H-pyrazole-5-carboxamide
Potential treatment - theoretical effect Experimental Antiviral Sep/21/2020
4-Phenylbutyric acid
Potential treatment - theoretical effect Used to treat other disease Antiviral Dec/10/2020
4-[(pyridin-3-ylmethyl) amino]-2H-chromen-2-one
Potential treatment - theoretical effect Experimental Antiviral Jul/16/2020
4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/28/2021
4-{[5-(2-Nitrophenyl)-2-furyl] methylene}-3-phenyl-5(4H)-isoxazolone
Potential treatment - theoretical effect Experimental Antiviral Nov/23/2020
4A10
Potential treatment - pre-clinical evidence Experimental Antiviral May/03/2020
4A12
Potential treatment - pre-clinical evidence Experimental Antiviral May/03/2020
4A3
Potential treatment - pre-clinical evidence Experimental Antiviral May/03/2020
4D5
Potential treatment - pre-clinical evidence Experimental Antiviral May/03/2020
4E1RCat
Potential treatment - theoretical effect Experimental Antiviral Nov/03/2020
4E2RCat
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
4SC-202
Potential treatment - theoretical effect Experimental Antiviral Sep/18/2020
5'END-1 PPMO
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/09/2020
5'END-2 PPMO
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/09/2020
5-(((4-nitrophenoxy)carbonyl)amino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-(3,4-Dimethoxyphenyl)-2-methyl-7-(5,6,7,8-tetrahydronaphthalen-2-yl)-5,7-dihydro-[1,3]thiazolo[3,2-a]pyrimidine-3,6-dione
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2021
5-(Acryloylamino)-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-(butylcarbamoylamino)-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
5-Imidazol-1-ylmethyl-quinolin-8-ol
Potential treatment - theoretical effect Experimental Antiviral Jan/27/2021